Skip to content
Pharma Observatory a Scientist.com platform

Condition (MeSH)

Astrocytoma

ClinicalTrials.gov lists 2,288 trials for Astrocytoma or a narrower condition beneath it. National Cancer Institute (NCI) has the most among industry and government lead sponsors, with 155.

MeSH D001254 Neoplasms Neoplasm C04
Email me this page as a PDF

Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Phase 1 Phase 1 694 Phase 1/2 Phase 1/2 295 Phase 2 Phase 2 647 Phase 2/3 Phase 2/3 17 Phase 3 Phase 3 115 Phase 4 Phase 4 8 Not applicable Not applicable 250 Observational Observational 244 Phase 1 Phase 1 694 Phase 1/2 Phase 1/2 295 Phase 2 Phase 2 647 Phase 2/3 Phase 2/3 17 Phase 3 Phase 3 115 Phase 4 Phase 4 8 Not applicable Not applicable 250 Observational Observational 244

Trials per phase (log scale)

1 more section with rows

675 of the 2,288 trials are tagged with Astrocytoma itself; the rest are tagged with a narrower condition beneath it.

Get the Astrocytoma report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

When did Astrocytoma trials start? (37)

Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year. 15 trials are registered to start in 2027 or later, and not listed here.

Trials over time, by phase

  • Phase 1
  • Phase 1/2
  • Phase 2
  • Phase 2/3
  • Phase 3
  • Phase 4
  • Not applicable
  • Observational

Top of scale: 115

1990: 1 trials (Phase 3 1) 1991: 1 trials (Phase 1 1) 1992: 2 trials (Observational 1, Phase 2 1) 1993: 3 trials (Phase 2 1, Phase 1/2 1, Phase 1 1) 1994: 8 trials (Phase 3 2, Phase 2 3, Phase 1 3) 1995: 8 trials (Observational 2, Phase 2 4, Phase 1 2) 1996: 14 trials (Not applicable 1, Phase 2 10, Phase 1 3) 1997: 15 trials (Observational 1, Phase 3 1, Phase 2 7, Phase 1/2 1, Phase 1 5) 1998: 28 trials (Not applicable 1, Phase 3 2, Phase 2/3 1, Phase 2 11, Phase 1/2 4, Phase 1 9) 1999: 31 trials (Observational 1, Phase 3 2, Phase 2 15, Phase 1/2 2, Phase 1 11) 2000: 38 trials (Phase 3 2, Phase 2 14, Phase 1/2 13, Phase 1 9) 2001: 37 trials (Observational 2, Not applicable 1, Phase 3 2, Phase 2 14, Phase 1/2 7, Phase 1 11) 2002: 43 trials (Observational 2, Phase 3 2, Phase 2 10, Phase 1/2 9, Phase 1 20) 2003: 29 trials (Observational 1, Phase 3 2, Phase 2 17, Phase 1/2 1, Phase 1 8) 2004: 46 trials (Observational 5, Not applicable 2, Phase 3 7, Phase 2 13, Phase 1/2 6, Phase 1 13) 2005: 69 trials (Observational 3, Not applicable 4, Phase 3 6, Phase 2 23, Phase 1/2 9, Phase 1 24) 2006: 68 trials (Observational 8, Not applicable 3, Phase 3 6, Phase 2 26, Phase 1/2 9, Phase 1 16) 2007: 69 trials (Observational 5, Phase 3 5, Phase 2/3 1, Phase 2 33, Phase 1/2 8, Phase 1 17) 2008: 73 trials (Observational 9, Not applicable 3, Phase 4 1, Phase 3 6, Phase 2 28, Phase 1/2 7, Phase 1 19) 2009: 80 trials (Observational 7, Phase 3 8, Phase 2 31, Phase 1/2 12, Phase 1 22) 2010: 83 trials (Observational 3, Not applicable 5, Phase 3 3, Phase 2 25, Phase 1/2 16, Phase 1 31) 2011: 78 trials (Observational 5, Not applicable 4, Phase 3 3, Phase 2/3 1, Phase 2 27, Phase 1/2 12, Phase 1 26) 2012: 66 trials (Observational 5, Not applicable 7, Phase 4 1, Phase 3 4, Phase 2/3 1, Phase 2 21, Phase 1/2 9, Phase 1 18) 2013: 75 trials (Observational 6, Not applicable 12, Phase 3 2, Phase 2 19, Phase 1/2 11, Phase 1 25) 2014: 81 trials (Observational 10, Not applicable 9, Phase 3 2, Phase 2/3 2, Phase 2 23, Phase 1/2 8, Phase 1 27) 2015: 72 trials (Observational 7, Not applicable 9, Phase 3 5, Phase 2/3 1, Phase 2 23, Phase 1/2 8, Phase 1 19) 2016: 95 trials (Observational 16, Not applicable 5, Phase 3 3, Phase 2 22, Phase 1/2 14, Phase 1 35) 2017: 93 trials (Observational 15, Not applicable 14, Phase 3 3, Phase 2/3 1, Phase 2 25, Phase 1/2 12, Phase 1 23) 2018: 114 trials (Observational 18, Not applicable 14, Phase 3 6, Phase 2/3 4, Phase 2 18, Phase 1/2 15, Phase 1 39) 2019: 85 trials (Observational 11, Not applicable 14, Phase 4 1, Phase 3 2, Phase 2/3 2, Phase 2 20, Phase 1/2 9, Phase 1 26) 2020: 99 trials (Observational 6, Not applicable 19, Phase 3 3, Phase 2/3 1, Phase 2 24, Phase 1/2 13, Phase 1 33) 2021: 90 trials (Observational 14, Not applicable 17, Phase 2 22, Phase 1/2 12, Phase 1 25) 2022: 115 trials (Observational 14, Not applicable 18, Phase 4 2, Phase 3 4, Phase 2 19, Phase 1/2 13, Phase 1 45) 2023: 106 trials (Observational 20, Not applicable 16, Phase 3 1, Phase 2 19, Phase 1/2 15, Phase 1 35) 2024: 109 trials (Observational 22, Not applicable 20, Phase 4 1, Phase 3 5, Phase 2/3 1, Phase 2 29, Phase 1/2 10, Phase 1 21) 2025: 109 trials (Observational 13, Not applicable 24, Phase 4 1, Phase 3 7, Phase 2 21, Phase 1/2 8, Phase 1 35)

Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.

Trials started per year
Year Trials started
2026 (partial year) 112
2025 109
2024 109
2023 106
2022 115
2021 90
2020 99
2019 85
2018 114
2017 93

Showing 10 of 37 earlier years.

Start your 14-day trial Email me all 37 earlier years as a PDF

Forecast of the full-year count, planned starts included, not rows of this table: about 120 trials starting in 2026 and about 120 in 2027, the average of the 24 months through September, counted as registered and carried forward. The rows of this table count trials registered so far with a start date in the year, planned starts included; the forecast looks ahead to the count for the whole year, so it is not the same measure. In backtests on conditions of this size, forecasts made part-way through the year were typically off by about 13 percent and ran about 12 percent low against the count later registered; forecasts made before the year began were off by about 19 percent and ran about 17 percent low against the count later registered, and had about the same error as repeating last year's count. These figures rest on a few years of history (target years from 2018 to 2025, varying by figure), place each condition as it is mapped today rather than as it was then, and score against a count for the newest year that was still being revised. Only condition series were scored.

Prediction, not a registry value: median of 36 months from start to primary completion across 304 trials still running at the 2026-10-09 snapshot; registered median of 42 months across 1,392 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.

What phase are Astrocytoma trials in? (9)

Shown in this order: phase order.

Show the trials by phase as a table
Trials by phase
Phase Trials
Phase 1 694
Phase 1/2 295
Phase 2 647
Phase 2/3 17
Phase 3 115
Phase 4 8
Not applicable 250
Observational 244
Expanded access 18

How many Astrocytoma trials are recruiting? (12)

Shown in this order: the order a trial moves through, from not yet recruiting to unknown.

Trials by recruitment status
Status Trials
Not yet recruiting 92
Recruiting 320
Enrolling by invitation 7
Active, not recruiting 173
Available 6

Showing 5 of 12 statuses.

Start your 14-day trial Email me all 12 statuses as a PDF

Status as registered on ClinicalTrials.gov. Each trial is counted once.

Which lead sponsors run the most Astrocytoma trials? (5)

Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.

Lead sponsors
Sponsor Trials
National Cancer Institute (NCI) 155
European Organisation for Research and Treatment of Cancer - EORTC 23
Novartis Pharmaceuticals 23
Children's Oncology Group 22
Pediatric Brain Tumor Consortium 20

Which drugs are being tested for Astrocytoma? (4)

Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.

Drugs tested
Drug Trials
Irinotecan 37
PEMBROLIZUMAB 36
NIVOLUMAB 29
Cytoxan 25

Interventions as named in the registry (11)

Shown in this order: most trials first.

Interventions as named in the registry
Drug Trials
SOC: Temozolomide 389
Radiation Therapy 154
Bevacizumab 1 128
Lomustine Pill 52
Radiotherapy 45

Showing 5 of 11 interventions.

Start your 14-day trial Email me all 11 interventions as a PDF

These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.

Which serious adverse events do Astrocytoma trials report? (10)

Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.

Serious adverse events in this condition's trials
Adverse event Subjects affected Trials
Seizure 917 195
Platelet count decreased 446 55
Headache 384 135
Fatigue 370 104
Vomiting 302 122

Showing 5 of 10 adverse events.

Start your 14-day trial Email me all 10 adverse events as a PDF

Which publications cover Astrocytoma? (202)

Shown in this order: major-topic papers first, then newest, then most linked to trials.

Publications
Publication Journal Year Major topic
Recombinant polio-rhinovirus immunotherapy for recurrent paediatric high-grade glioma: a phase 1b trial. The Lancet. Child & adolescent health 2023 Yes
Phase II Randomized Trial of Lenalidomide in Children With Pilocytic Astrocytomas and Optic Pathway Gliomas: A Report From the Children's Oncology Group. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2023 Yes
Therapy for Diffuse Astrocytic and Oligodendroglial Tumors in Adults: ASCO-SNO Guideline. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2022 Yes
GD2-CAR T cell therapy for H3K27M-mutated diffuse midline gliomas. Nature 2022 Yes
Temozolomide and Radiotherapy versus Radiotherapy Alone in Patients with Glioblastoma, IDH-wildtype: Post Hoc Analysis of the EORTC Randomized Phase III CATNON Trial. Clinical cancer research : an official journal of the American Association for Cancer Research 2022 Yes

Showing 5 of 202 publications.

Start your 14-day trial Email me the first 50 publications as a PDF

Prevalence (50)

Shown in this order: jurisdiction, then disease name. Orphanet observation for the mapped ORPHA concept; the mapping relation column says whether that concept is exactly this condition or broader or narrower.

Prevalence
Orphanet disease Type Class Geography Jurisdiction Mapping relation
Astrocytoma Annual incidence 1-9 / 100 000 United Kingdom GB Exact
Astrocytoma Annual incidence 1-9 / 100 000 United Kingdom GB Exact
Astrocytoma Annual incidence 1-9 / 100 000 Lithuania Not stated Exact
Astrocytoma Annual incidence 1-9 / 100 000 Ireland Not stated Exact
Astrocytoma Annual incidence 1-9 / 100 000 Croatia Not stated Exact

Showing 5 of 50 prevalence observations.

Start your 14-day trial Email me all 50 prevalence observations as a PDF

Rare-disease identity (2)

Shown in this order: exact, broader, narrower, other.

Rare-disease identity
Orphanet disease ORPHA code Relation Source
Astrocytoma 94 Exact Orphanet Rare Disease Ontology (ORDO)
Astrocytoma 94 Exact Orphadata Science knowledge files, Product 1

Sub-conditions in MeSH (1)

MeSH descendants one level down with at least one trial, most trials first.

Not on this page

Not measured: delivery record.

Browse all condition evidence pages